CD19

    Hematopathology
    ZM179 Monospecific Mouse Monoclonal

    Zeta CD19 Antibody.  Zeta’s recombinant mouse antibody recognizes CD19, which is expressed on pre-B cells and the majority of B-cell neoplasms.  In normal lymphoid tissue CD19 is observed in germinal centers (on both B cells and follicular dendritic cells), in mantle zone cells and in scattered cells in the interfollicular areas, with an overall immunoreactivity pattern similar to that of CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in pre-B cells. CD19 positivity is seen in the vast majority of B-cell neoplasms (B-lymphoblastic lymphoma, small lymphocytic lymphoma/CLL, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell-rich B-cell lymphoma, lymphoblastic lymphoma, hairy cell leukemia) and commonly at a lower intensity than normal B-cell elements. Plasma cell neoplasms are consistently negative as are T-cell neoplasms. CD19 was undetectable in 14% of diffuse large B-cell lymphomas, 30% of T-cell-rich B-cell lymphomas and 75% of post-transplant B-lymphoproliferative disease. CD19 expression is not seen in Reed Sternberg cells of classic Hodgkin lymphoma.

    CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. The antibody to CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always CD19 negative, as are T-cell neoplasms.

    Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists.  Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.

    Specifications
    Species Reactivity:Humans; others not tested
    Known Applications:Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
    Supplied As:Buffer with protein carrier and preservative
    Storage:Store at 2ºC to 8ºC
    Control:Lymph node or tonsil
    Visualization:Membranous
    Isotype:IgG2a /κ
    Immunogen:A synthetic peptide from the c-terminus of human CD19 protein
    Ordering Information
    Classification IVD
    Catalogue Number Z2481ML
    Classification IVD
    Catalogue Number Z2481ML
    Package Inserts
    IFU-CD19 ZM179 - IVD
    Regulatory Notice
    Product classification varies based on regulations of individual countries. Please contact your local distributor for more information. Products labeled as ASR or RUO in the US might be available as IVD or RUO in respective countries.
    SDS
    SDS